RT Journal Article
SR Electronic
T1 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 180
VO 42
IS Suppl 57
A1 Jadwiga A. Wedzicha
A1 Marc Decramer
A1 Joachim H. Ficker
A1 Angel FowlerTaylor
A1 Peter D'Andrea
A1 Christie Arrasate
A1 Hungta Chen
A1 Donald Banerji
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/180.abstract
AB IntroductionGlycopyrronium (NVA237) and tiotropium (TIO) are once-daily (OD) inhaled long-acting muscarinic antagonists for the treatment of COPD. Here we present the efficacy results of glycopyrronium (GLY) vs TIO in patients with COPD from the SPARK study.MethodsThis 64-week, multicenter, parallel-group, active-controlled study randomized patients ≥40 yrs with severe-to-very severe COPD and a history of exacerbations to receive double-blind QVA149 110/50µg or GLY 50µg or open-label TIO 18µg OD. COPD exacerbations, lung function (pre-dose forced expiratory volume in 1 second [FEV1]), St. George’s Respiratory Questionnaire (SGRQ) scores and rescue medication use were analyzed.Results1483 patients were randomized, 99.5% analyzed (GLY=739, TIO=737); male: 74%. At Week 64, the reduction in the rate of COPD exacerbations in the GLY group was comparable to TIO (Rate ratio [RR]: 1.01, 95% confidence interval [CI]: 0.913, 1.107, p=0.919). The pre-dose FEV1 (LS Mean [SE], L) was similar for GLY (0.98 [0.011]) and TIO (0.99 [0.011]). SGRQ score improvement (LS Mean [SE]) with GLY (45.46 [0.780]) was similar to TIO (46.08 [0.778]). The reduction in daily rescue medication usage was comparable for both GLY and TIO.ConclusionOnce-daily GLY showed similar efficacy in reducing exacerbations, improving lung function and health status, and reducing rescue medication use as TIO in patients with severe-to-very severe COPD.